2023
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
de Mesquita Y, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao E, Carvalho P, da Silva C, Cardoso R, Moura F, Rafalskiy V. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. International Journal Of Obesity 2023, 47: 883-892. PMID: 37460681, DOI: 10.1038/s41366-023-01337-x.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsRandomized Controlled Trials as TopicWeight LossConceptsMean differenceRandomized controlled trialsOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsControlled trialsMeta-analysisCo-primary endpointsMethodsWe searched PubMedType 2 diabetesAgonist tirzepatideRisk of biasReview Manager 5.4.1Receptor agonistsReduced BMITherapeutic optionsWaist circumferenceAdverse eventsTirzepatideGastrointestinal symptomsPooled analysisGLP-1PlaceboWeight management
2022
Tirzepatide for diabetes: on track to SURPASS current therapy
Moura F, Scirica B, Ruff C. Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine 2022, 28: 450-451. PMID: 35260841, DOI: 10.1038/s41591-022-01733-2.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesDiabetes MellitusGastric Inhibitory PolypeptideHumansHypoglycemic Agents